- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01562522
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study. (EXPEDIENT)
November 6, 2019 updated by: Ipsen
The purpose of the protocol, is to assess the feasibility of conducting a larger trial to evaluate the effect of a psychological intervention on the well-being of patients on luteinizing hormone-releasing hormone (LHRH) analogs in the treatment of prostate cancer and their partners.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nieuwegein, Netherlands
- St. Antonius Hospital
-
Utrecht, Netherlands
- Diakonessenhuis
-
Woerden, Netherlands
- Zuwe Hofpoort Ziekenhuis Woerden, Netherlands
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of prostate cancer on biopsy
- Locally advanced or metastasised prostate cancer in need of hormonal treatment.
- On LHRH analogue treatment for a minimum of 5 months (at inclusion)
- Having a female partner
- Patients and their partner are able to fill out questionnaires, attend group sessions and give consent
Exclusion Criteria:
- Serious psychiatric difficulties
- Life expectancy < 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: Control group
|
|
|
EXPERIMENTAL: Intervention group
|
Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation.
Total intervention time: 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sufficient interest in participation
Time Frame: Up to the end of 16 weeks of the intervention period
|
Determined by achievement of all of the following:
|
Up to the end of 16 weeks of the intervention period
|
|
Preliminary improvement in well-being
Time Frame: After the intervention period of 16 weeks
|
Improved - Group 1 improve more than group 2 on at least one of the outcome measures (includes HADS, EORTC QLQ-C30 or Maudsley Marital Questionnaire). Worsened - Group 1 should not worsen more than group 2 on any of the outcome measures. |
After the intervention period of 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in quality of life questionnaire QLQ-C30 scores
Time Frame: Baseline (T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
Baseline (T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
|
Change in quality of life questionnaire QLQ-PR25 scores
Time Frame: Baseline(T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
Baseline(T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
|
Difference in relationship satisfaction (Maudsley Marital Questionnaire)
Time Frame: Baseline (T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
Baseline (T0), after the intervention period of 16 weeks (T1) and 1 year (T2)
|
|
Difference between level of depression and anxiety (HADS)
Time Frame: Baseline (T0) and 1 year (T2)
|
Baseline (T0) and 1 year (T2)
|
|
Change in Hospital Anxiety and Depression Scale (HADS) scores
Time Frame: Baseline (T0), after the intervention period of 16 weeks (T1)
|
Baseline (T0), after the intervention period of 16 weeks (T1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
July 1, 2013
Study Completion (ACTUAL)
July 1, 2013
Study Registration Dates
First Submitted
March 21, 2012
First Submitted That Met QC Criteria
March 23, 2012
First Posted (ESTIMATE)
March 26, 2012
Study Record Updates
Last Update Posted (ACTUAL)
November 7, 2019
Last Update Submitted That Met QC Criteria
November 6, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-95-52014-192
- 2011-004819-24 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.